Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
2.
J Neurol ; 267(10): 3054-3060, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-32524258

RESUMO

OBJECTIVE: Dyspnea can be present as non-motor symptom in patients with Parkinson's disease (PD). Deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves motor and non-motor symptoms in PD. However, new-onset dyspnea has been reported after DBS surgery. We have studied respiratory characteristics of PD patients with bilateral STN-DBS to assess the impact of DBS on pulmonary function. METHODS: STN-DBS PD patients with dyspnea after surgery (cases) were matched with STN-DBS PD patients without dyspnea (controls). Motor and pulmonary function were assessed with stimulation and without medication (on stim/off med), and without stimulation and medication (off stim/off med). Pulmonary function was investigated with spirometry and dyspnea with the Medical Research Council Dyspnea Scale (MRCDS) and the Borg Scale (BS). RESULTS: Seven cases (five men, 58.30 ± 6.70 years of age) and seven controls (six men, 61.10 ± 6.30 years of age) were enrolled. MRCDS and BS revealed the presence of dyspnea in both groups. No significant changes in pulmonary function were found in both cases and controls in on stim/off med vs. off stim/off med condition (p < 0.05), and in cases vs. controls in on stim/ off med condition (p < 0.05). CONCLUSIONS: No impact of STN-DBS on pulmonary function was found in cases. Impaired perception of dyspnea and spread of stimulation surrounding the STN might account for new-onset dyspnea after DBS surgery. Dyspnea was detected also in controls using ad hoc questionnaires. Our findings suggest further investigation of this non-motor symptom in PD patients.


Assuntos
Estimulação Encefálica Profunda , Dispneia , Doença de Parkinson , Estudos de Casos e Controles , Dispneia/etiologia , Dispneia/terapia , Humanos , Masculino , Doença de Parkinson/complicações , Doença de Parkinson/terapia , Resultado do Tratamento
3.
J Clin Exp Hepatol ; 9(1): 74-98, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30765941

RESUMO

Clinical practice guidelines for Wilson's disease (WD) have been published by the American Association for the Study of Liver Diseases and European Association for the Study of the Liver in 2008 and 2012, respectively. Their focus was on the hepatic aspects of the disease. Recently, a position paper on pediatric WD was published by the European Society of Pediatric Gastroenterology Hepatology and Nutrition. A need was felt to harmonize guidelines for the hepatic, pediatric, and neurological aspects of the disease and contextualize them to the resource-constrained settings. Therefore, experts from national societies from India representing 3 disciplines, hepatology (Indian National Association for Study of the Liver), pediatric hepatology (Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition), and neurology (Movement Disorders Society of India) got together to evolve fresh guidelines. A literature search on retrospective and prospective studies of WD using MEDLINE (PubMed) was performed. Members voted on each recommendation, using the nominal voting technique. The Grades of Recommendation, Assessment, Development and Evaluation system was used to determine the quality of evidence. Questions related to diagnostic tests, scoring system, and its modification to a version suitable for resource-constrained settings were posed. While ceruloplasmin and 24-h urine copper continue to be important, there is little role of serum copper and penicillamine challenge test in the diagnostic algorithm. A new scoring system - Modified Leipzig score has been suggested with extra points being added for family history and serum ceruloplasmin lower than 5 mg/dl. Liver dry copper estimation and penicillamine challenge test have been removed from the scoring system. Differences in pharmacological approach to neurological and hepatic disease and global monitoring scales have been included. Rising bilirubin and worsening encephalopathy are suggested as indicators predicting need for liver transplant but need to be validated. The clinical practice guidelines provide recommendations for a comprehensive management of WD which will be of value to all specialties.

5.
Stereotact Funct Neurosurg ; 93(1): 59-65, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25662728

RESUMO

The pedunculopontine nucleus (PPN) is a potential target for gait disorders. We report 4 cases of bilateral PPN stimulation in progressive supranuclear palsy (PSP) patients with short-term (6 months) and long-term (18 months) follow-ups. Patients with PSP who had gait disturbances, but were able to walk with or without assistance, were selected. The patients' median age was 64 years and the disease duration 3 years. Bilateral PPN deep brain stimulation (DBS) was performed. The pacemaker was programmed using a bipolar mode and lower frequencies (20-45 Hz). The PSP rating scores (PSPRS) and their gait subscores (No. 25, 26, 27 and 28) along with PSP staging scores were used as primary end points. The total Unified Parkinson's Disease Rating Scale (UPDRS), UPDRS III and the 39-item Parkinson's Disease Questionnaire were considered as secondary end points. Video recordings of the gaits were performed before surgery and at the 6- and 18-month follow-ups. These were retrospectively reviewed by a blinded neurologist for the primary end points. At the 6- and 18-month follow-ups, the median change in PSPRS was from 33 (baseline) to 37.5 and 47, respectively. Similarly, the PSP staging changed from 3 to 2.5 and 3.5, item 25 from 1.5 to 2 and 3.5, item 26 from 2.5 to 2 and 3.5, item 27 from 3.5 to 3 and 3.5 and item 28 from 1.5 to 1.5 and 3. Two patients in the study with the PSP-parkinsonism phenotype experienced improvement in their gait until the last follow-up. Bilateral PPN DBS can be safely performed in PSP patients despite mid-brain atrophy.


Assuntos
Estimulação Encefálica Profunda , Transtornos Neurológicos da Marcha/terapia , Núcleo Tegmental Pedunculopontino/fisiopatologia , Paralisia Supranuclear Progressiva/terapia , Idoso , Atrofia , Feminino , Seguimentos , Transtornos Neurológicos da Marcha/etiologia , Transtornos Neurológicos da Marcha/fisiopatologia , Humanos , Masculino , Mesencéfalo/patologia , Pessoa de Meia-Idade , Núcleo Tegmental Pedunculopontino/patologia , Estudos Retrospectivos , Método Simples-Cego , Paralisia Supranuclear Progressiva/complicações , Resultado do Tratamento
6.
J Neurol Neurosurg Psychiatry ; 82(4): 364-8, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20667867

RESUMO

Camptocormia or 'bent spine syndrome' is a rare manifestation of Parkinson's disease. The postural deformity can be a great source of disability. Camptocormia is typically not responsive to dopaminergic medication. Results with deep brain stimulation to treat camptocormia have been mixed but generally poor. The authors report two cases of camptocormia in Parkinson's disease treated with spinal corrective surgery. Despite prolonged postoperative courses, including a high complication rate and the need for multiple revisions, both patients benefited from the procedures.


Assuntos
Cifose/cirurgia , Doença de Parkinson/cirurgia , Idoso , Humanos , Cifose/complicações , Masculino , Atrofia Muscular Espinal/complicações , Atrofia Muscular Espinal/cirurgia , Doença de Parkinson/complicações , Curvaturas da Coluna Vertebral/complicações , Curvaturas da Coluna Vertebral/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA